Products - Autoimmune - Rheumatology -
Connective tissue diseases (CTD) are rheumatic diseases. They include, for example, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, myositis syndromes or Sharp syndrome.
Autoantibodies against cellular components, commonly called anti-nuclear antibodies (ANA), are important serological markers for CTD. Target antigens include nucleic acids, cell nuclear proteins and ribonuclear proteins as well as components of the cytoplasm. The frequency (prevalence) of ANA in inflammatory rheumatic diseases lies between 20% and 100%. Differential ANA diagnostics is therefore indispensable for the identification of individual rheumatic diseases and their differentiation from other autoimmune diseases.
For Research Use Only. Not For Use In Diagnostic Procedures.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.
wdt_ID | Method | Parameter | Substrate | Species/ Antigen |
---|---|---|---|---|
186 | IFA | cell nuclei (ANA) EUROPattern cell nuclei (ANA) |
cell nuclei (ANA) HEp-2 cells liver (2 BIOCHIPs per field) |
human monkey |
187 | IFA | cell nuclei (ANA global test) |
HEp-2 cells liver (2 BIOCHIPs per field) |
human monkey |
188 | IFA | EUROPLUS ANA Mosaic 10 cell nuclei (ANA) SS-A + SS-B |
2 BIOCHIPs per field: HEp-2 cells SS-A+SS-B BIOCHIPs |
human |
189 | IFA | ANA Mosaic 2 EUROPattern cell nuclei (ANA), EUROPattern mitochondria (AMA) |
2 BIOCHIPs per field: HEp-2 cells kidney |
human rat |
190 | IFA | cell nuclei (ANA) mitochondria (AMA |
HEp-2 cells kidney (2 BIOCHIPs per field) |
human rat |
191 | IFA | cell nuclei (ANA) EUROPattern cell nuclei (ANA) |
HEp-20-10 cells liver (2 BIOCHIPs per field) |
human monkey |
192 | IFA | cell nuclei (ANA global test) |
HEp-20-10 cells liver (2 BIOCHIPs per field) |
human monkey |
193 | IFA | EUROPLUS ANA Mosaic 10A cell nuclei (ANA) SS-A + SS-B |
2 BIOCHIPs per field: HEp-20-10 cells SS-A+SS-B BIOCHIPs |
human |
194 | IFA | cell nuclei (ANA) mitochondria (AMA) |
HEp-20-10 cells kidney (2 BIOCHIPs per field) |
human rat |
195 | IFA | EUROPLUS ANA Mosaic 20A cell nuclei (ANA) cell nuclei (ANA) SS-A + SS-B ribosomal P-proteins + Jo-1 |
4 BIOCHIPs per field: HEp-20-10 cells liver SS-A+SS-B BIOCHIPs rib. P-prot.+Jo-1 BIOCHIPs |
human monkey |
196 | IFA | EUROPLUS ANA Mosaic 22A cell nuclei (ANA) cell nuclei (ANA) nRNP/Sm + Sm + SS-A SS-B + Scl-70 + Jo-1 |
4 BIOCHIPs per field: HEp-20-10 cells liver nRNP/Sm+Sm+SS-A BIOCHIPs SS-B+Scl-70+Jo-1 BIOCHIPs |
human monkey |
197 | IFA | cell nuclei (ANA) cell nuclei (ANA) |
HEp-20-10 cells liver (2 BIOCHIPs per field) |
human rat |
198 | IFA | cell nuclei (ANA) | HEp-2 cells | human |
199 | IFA | cell nuclei (ANA) EUROPattern |
HEp-2 cells | human |
200 | IFA | cell nuclei (ANA) | HEp-20-10 cells | human |
201 | IFA | cell nuclei (ANA) EUROPattern |
HEp-20-10 cells | human |
202 | EUROLINE | Myositis Profile (Mi-2, Ku, PM-Scl, Jo-1, PL-7, PL-12, Ro-52 separately) |
EUROLINE | |
203 | EUROLINE | positive control serum: IgG, human, 100x concentrated for DL 1530-X G |
||
204 | EUROLINE | Myositis Profile 3 (Mi-2, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52 separately) |
EUROLINE | |
205 | EUROLINE | Autoimmune Inflammatory Myopathies 16 Ag (Mi-2 alpha, Mi-2 beta, TIF1g, MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52 separately) |
EUROLINE | |
206 | EUROLINE | Autoimmune Inflammatory Myopathies 16 Ag et cN-1A (Mi-2 alpha, Mi-2 beta, TIF1g, MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52, cN-1A separately) |
EUROLINE | |
207 | EUROLINE | positive control serum: IgG, human, 100x concentrated for DL 1532 G |
||
208 | EUROLINE | Systemic Sclerosis Profile (Nucleoli) (Scl-70, CENP A, CENP B, RP11, RP155, fibrillarin, NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR, Ro-52 separately) |
EUROLINE | |
209 | ELISA | histones | antigen-coated microplate wells |
native, highly purified histones, bovine thymus |
210 | IFA | antibodies against cell nuclei (ANA control), homogeneous pattern |
2024 EUROIMMUN US
Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap